Medical Oncology

Vitreoretinal Diseases and Surgery

Questions discussed in this category

How do you manage the severe adverse drug reaction of central serous retinopathy with MEK inhibitors?

If a patient develops central serous retinopathy on a MEK inhibitor despite dose reductions, is it ok to switch to a different BRAF/MEK combination?

1 Answer available

How do you manage MEK inhibitor induced ocular adverse events?

1 Answer available

Papers discussed in this category

JAMA ophthalmology, 2016-08-01

Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.

Related Topics in Medical Oncology